Currently, there are four main treatments propelling this market forward: Ozempic and Wegovy (semaglutide: a GLP-1 agonist, developed by Novo Nordisk) Mounjaro and Zepbound (tirzepatide: a dual agonist targeting both GLP-1 and GIP (Gastric inhibitory polypeptide) receptors, developed by Eli Lilly) These medications are administered subcutaneously with the assistance of injection pens
The most common players in the lab are: Dimethyl sulfoxide (DMSO) Dimethylformamide (DMF) Acetonitrile (ACN) The trick here is to be strategic
Conversely, if your research involves injectable BPC-157, you can breathe easy
Test Yourself With Our Latest Lifestyle Quiz That list includes active ingredients that state-licensed pharmacies are legally permitted to use for compounding prescription drugs, Tatem said
Insurance coverage for therapeutic peptides remains limited, as most insurers classify them as experimental or investigational treatments
Request your appointment to get started, or find out more about Dr